secwatch.observer — SEC 8-K summary
======================================

Issuer:     TAO Synergies Inc. (TAOX)
CIK:        0001571934
Form:       8-K
Filed at:   2023-07-19T23:59:59+00:00
Accession:  0001104659-23-082211
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Synaptogenix partners with Cleveland Clinic for Phase 1 Bryostatin-1 trial in multiple sclerosis
--------------------------------------------------------------------------------

- Agreement with Cleveland Clinic to conduct Phase 1 trial of Bryostatin-1 in multiple sclerosis; IND submission to FDA planned.
- Trial expected to commence in Q4 2023 at Cleveland Clinic's Mellen Center for Multiple Sclerosis.
- Synaptogenix had approximately $35.8M in cash as of March 31, 2023, sufficient to fund the trial and other developments.
- Bryostatin-1 targets synaptic regeneration and anti-inflammatory pathways; cognitive impairment is a key unmet need in MS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1571934/000110465923082211/0001104659-23-082211-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1571934/000110465923082211/tm2321611d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-082211

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer